Actively Recruiting
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Led by Beijing InnoCare Pharma Tech Co., Ltd. · Updated on 2025-09-15
324
Participants Needed
19
Research Sites
322 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
CONDITIONS
Official Title
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Confirmed diagnosis of B-cell non-Hodgkin lymphoma marginal zone lymphoma (splenic, nodal, or extra-nodal)
- Prior systemic therapy including at least one anti-CD20 monoclonal antibody regimen with minimum 2 completed cycles for combination therapies or minimum 4 doses for monotherapy, unless disease progressed during treatment
- Relapsed or refractory disease status
- At least one measurable lesion confirmed by enhanced CT or MRI
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
You will not qualify if you...
- Received specified anti-tumor therapies within 2 weeks before starting study treatment
- Received any other investigational product within 4 weeks before study treatment or currently in another clinical trial (except long-term follow-up after discontinuation)
- Prior treatment with any Bruton tyrosine kinase (BTK) inhibitor
- Refractory to lenalidomide plus rituximab (R2 regimen), defined as failure to achieve at least partial response after adequate R2 treatment or disease progression during or within 6 months after R2 therapy
- Lymphoma involving the central nervous system or meningeal involvement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Auhui, China, 233000
Actively Recruiting
2
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
3
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
4
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510055
Actively Recruiting
5
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, China, 510120
Actively Recruiting
6
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
7
Henan Provincial Peoples Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
8
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
9
Hunan Cancer Hospital
Changsha, Hunan, China, 410000
Not Yet Recruiting
10
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Actively Recruiting
11
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China, 330029
Actively Recruiting
12
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China, 116023
Actively Recruiting
13
The first Hospital of China Medical University
Shenyang, Liaoning, China, 110002
Actively Recruiting
14
The Affiliated Hospital Of Qingdao University
Qingdao, Shandong, China, 266000
Not Yet Recruiting
15
Yantai Yuhuangding Hospital
Yantai, Shandong, China, 264099
Actively Recruiting
16
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200040
Actively Recruiting
17
The Second Affiliated Hospital of Xi'an Jiaotong University（Xibei Hospital）
Xi’an, Shanxi, China, 710004
Actively Recruiting
18
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041
Not Yet Recruiting
19
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
A
Alexia Lu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here